Arcus Biosciences' stock rating and price were influenced by analyst reports, and the company filed with the SEC regarding institutional purchases.

The entities involved

• Arcus Biosciences →

  biopharmaceutical company

  Nothing else this week.

• Leerink partners →

  U.S. investment bank

  • Leerink Partners provided coverage and price targets for Freenome on September 26, 2026.Fri 19:28
  • Leerink Partners started coverage on ANI Pharmaceuticals shares.Fri 05:52
• SEC →

  Slovak company

  • Director Arne Wilhelmsen sold shares of Royal Caribbean Cruises Ltd. and disclosed the transaction to the SEC.Sat 01:15
  • Director Lisa Jamieson sold shares of Forestar Group stock and disclosed the transaction to the SEC.Sat 00:53
• SEC →

  Slovak company

  • Insider sale disclosed in SEC filing involving Kevin Mcculloch.Sat 00:45
  • Simwon America Corp. debuted on Nasdaq and filed with the SEC, with WallachBeth Capital running the book on the deal.Sat 00:39

Related events

• Analyst rating targets are affecting stock prices, and required reports regarding ownership stakes are being filed with the SEC for Bank of America and KBR, Inc.Sep 9
• Assembly Biosciences stock traded on Nasdaq, while UBS cut its price target but maintained a Buy rating, following an SEC disclosure.Wed 00:24
• Analyst reports inform market sentiment regarding filings involving Keefe, Bruyette & Woods and the SEC.Jun 25
• Wholesale Club filed a disclosure document with the SEC, coinciding with UBS increasing its price target.Aug 27
• Nucor made disclosures with the SEC regarding its stock holdings and performance on July 3, 2026.Jul 3